Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

Lilly also recently announced that it is acquiring a clinical stage drug known as STX-478 from Scorpion Therapeutics for up to $2.5 billion. Lilly's long-term potential doesn't hinge on GLP-1 ...

GlaxoSmithKline's head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion Therapeutics. Hoos is leaving GSK after nine ...

Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive ...

Relay Therapeutics Inc. (NASDAQ:RLAY) is a leading clinical-stage precision medicines firm focused on cancer treatments. The ...